The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday.

"“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirl" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site ...

The company's latest attempt at a weight loss drug, CagriSema, matched the bar set by a currently approved medicine but still didn't surpass it. Since Ozempic blasted onto the stage in 2017 with ...

REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual ...

CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial ...

Novo Nordisk’s shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

05:57 EST Novo Nordisk (NVO) says patients on Cagrisema lost 22.7% of weight in trial Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming ...

06:01 EST Novo Nordisk (NVO) shares drop 27% premarket after releasing Cagrisema data Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...